Business Wire

Mauritius Telecom and Aprecomm Come Together to Bring Innovation to Customer Experience With Network Intelligence

28.2.2023 14:58:00 EET | Business Wire | Press release

Share

Mauritius Telecom, the largest ISP in Mauritius with cellular and high-speed broadband service distribution, today announced its intent to bring Artificial Intelligence based innovative technology to enhance visibility and optimize its residential Wi-Fi connections through a partnership with Aprecomm. This A.I. technology will help Mauritius Telecom to bring proactive Network Intelligence transformation to improve customer experience and to drastically reduce the time for resolution of customer-end issues across their broadband network covering more than 300,000 households.

Speaking on the development, Mr. Kapil Reesaul, CEO, Mauritius Telecom, said, “Mauritius Telecom is the forefront runner in continuous investments in technology to keep innovating and providing the best service to its consumers. The partnership with Aprecomm will help us in our efforts to ensure the best experience across our broadband consumers with faster and proactive resolution of potential issues.”

Pramod Gummaraj, CEO, Aprecomm, said, “We're excited to team up with Mauritius Telecom and implement cutting-edge technology into their network in order to help them cut down on support ticket response times by as much as half and provide a dramatically better experience for their customers. Network Innovation focused on customer experience could be deployed across in the coming months.”

The measurable improvements offered by the integration between Mauritius Telecom and Aprecomm also lead to lower maintenance cost and improved customer satisfaction for one of the country’s fastest growing ISPs.

“With Aprecomm’s vendor agnostic technology, Mauritius Telecom will be able to manage and monitor Network Elements through a unified interface, ensuring assured internet experience to their customers,” said Guharajan Sivakumar, CTO, Aprecomm.

“Network Automation will allow us to bring the best possible experience to our end customers. Measurable customer experience and proactive actions to improve it will be part of this partnership as Aprecomm technology is aligned towards Network Automation,” said Mr. Yagianath Rosunee, CTO of Mauritius Telecom.

About Mauritius Telecom

Mauritius Telecom is the leading provider of an extensive range of ICT services and solutions for both residential customers and businesses in Mauritius, including fixed, mobile, broadband, TV, mobile money and ICT services. Mauritius Telecom has played a pivotal role in the socio-economic development of Mauritius, paving the way for the growth of the ICT industry, which has become a major pillar of the Mauritian economy. Mauritius Telecom has taken bold initiatives to transform the lives of Mauritians, deploying fibre island-wide to provide ultra-high-speed broadband to all, disrupting the payment landscape with a mobile wallet thus revolutionizing payments in Mauritius, launching in 2021 the first 5G Experience Zones and the first 1Gbps fibre internet to home offer in Mauritius. In 2022 Mauritius Telecom’s mobile service, my.t mobile reached the milestone of one million customers.

About Aprecomm

Aprecomm is an industry game-changer with a Network Intelligence Software Stack to understand Customer Experience. Aprecomm offers cloud-based automated solutions to enhance Wired and Wi-Fi network performance. Aprecomm’s patented technology helps in automatically and proactively troubleshooting Wi-Fi issues. This way ISPs and Enterprises will be able to fix them immediately and dramatically minimize down-time. Aprecomm’s solutions help enterprises, ISPs, TSPs improve their business standards through higher reliability, reduced expenses, and speedy ROI.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further details please contact:
Aprecomm
Shankar Peerthy
Email: Peerthy@aprecomm.ai
Contact: +41-78 685 82 58

About Business Wire

Business Wire
Business Wire



http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye